Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||84.01 - 85.00|
|52 Week Range||24.55 - 92.97|
|PE Ratio (TTM)||11.74|
|Dividend & Yield||3.30 (3.40%)|
|1y Target Est||N/A|
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
Sanofi and Alnylam Pharmaceuticals Inc. on Wednesday reported positive results in a late-stage trial of a treatment for Hereditary ATTR (hATTR) Amyliodosis patients with polyneuropathy. Alnylam shares ...